Amylyx CLO sells 30,000 shares in planned trades

Amylyx Pharmaceuticals, Inc. insider Gina Mazzariello, Chief Legal Officer, reported two open-market sales of common stock.

Rhea-AI Filing Summary

Amylyx Pharmaceuticals, Inc. insider Gina Mazzariello, Chief Legal Officer, reported two open-market sales of common stock. On July 9, 2026, she sold 15,000 shares at a weighted average price of $18.3164 per share, and on July 10, 2026 she sold another 15,000 shares at a weighted average price of $17.6081 per share. The filing states that these sales were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026. Following the transactions, she holds 179,090 shares of Amylyx Pharmaceuticals common stock directly.

Filing Explained

The officer’s disclosed direct position is 179,090 shares after two reported plan-based sales.

This Form 4 reports two 15,000-share sales of Amylyx common stock by Chief Legal Officer Gina Mazzariello on July 9 and July 10, 2026; the reported transactions leave her direct holdings at 179,090 shares, after the first transaction showed 194,090 shares.

Both transactions use code S, which identifies them as open-market sales under the Form 4 code definitions.

The filing states that both sales were effected under a Rule 10b5-1 trading plan adopted on April 9, 2026; that disclosure identifies the plan’s adoption date, not the reasons for these individual trades.

The reported prices are weighted averages: $18.3164 for the July 9 sale, with transactions ranging from $17.92 to $18.51, and $17.6081 for the July 10 sale, with transactions ranging from $17.15 to $18.07.

Insider Trade Summary 10b5-1

Net Seller: 30,000 shares

Net Sell 2 txns

Insider Mazzariello Gina

Role Chief Legal Officer

Sold 30,000 shs ($539K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F3	15,000	$17.6081	$264K
Sale	Common Stock F1, F2	15,000	$18.3164	$275K

Holdings After Transaction: Common Stock — 179,090 shares (Direct)

Footnotes (3)

1. F1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.92 to $18.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.15 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Key Figures

Shares sold total: 30,000 shares Sale on July 9, 2026: 15,000 shares at $18.3164 Sale on July 10, 2026: 15,000 shares at $17.6081 +4 more

7 metrics

Shares sold total 30,000 shares Combined open-market sales on July 9 and 10, 2026

Sale on July 9, 2026 15,000 shares at $18.3164 Weighted average price for that day’s open-market sale

Sale on July 10, 2026 15,000 shares at $17.6081 Weighted average price for that day’s open-market sale

Price range footnote (first sale) $17.92 to $18.51 Range of individual trade prices underlying one weighted average

Price range footnote (second sale) $17.15 to $18.07 Range of individual trade prices underlying one weighted average

Shares owned after transactions 179,090 shares Direct ownership of common stock following July 10, 2026 sale

10b5-1 plan adoption date April 9, 2026 Date the trading plan governing these sales was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, beneficial ownership

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale market

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

beneficial ownership regulatory

"Full information regarding the number of shares sold at each separate price can be furnished"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Amylyx Pharmaceuticals (AMLX) report for Gina Mazzariello?

Amylyx Pharmaceuticals reported that Chief Legal Officer Gina Mazzariello sold a total of 30,000 common shares in two open-market transactions on July 9 and 10, 2026 under a Rule 10b5-1 trading plan.

How many Amylyx Pharmaceuticals (AMLX) shares did Gina Mazzariello sell and at what prices?

Gina Mazzariello sold 15,000 shares at a weighted average price of $18.3164 on July 9, 2026, and 15,000 shares at a weighted average price of $17.6081 on July 10, 2026, in open-market sales.

How many Amylyx Pharmaceuticals (AMLX) shares does Gina Mazzariello hold after these sales?

After the reported transactions, Chief Legal Officer Gina Mazzariello holds 179,090 shares of Amylyx Pharmaceuticals common stock directly, as disclosed in the Form 4 filing for the July 10, 2026 transaction.

Were Gina Mazzariello’s Amylyx Pharmaceuticals (AMLX) share sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales by Chief Legal Officer Gina Mazzariello were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026, indicating they were pre-arranged.

Did the Amylyx Pharmaceuticals (AMLX) Form 4 specify price ranges for the insider sales?

Yes. The filing notes that the reported weighted average prices reflect multiple trades, with shares sold in ranges of $17.92–$18.51 for one date and $17.15–$18.07 for the other, with full breakdowns available to SEC staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 04:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazzariello Gina

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		S(1)		15,000	D	$18.3164(2)	194,090	D
Common Stock	07/10/2026		S(1)		15,000	D	$17.6081(3)	179,090	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 9, 2026.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.92 to $18.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.15 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

	/s/ Joshua B. Cohen, as Attorney in Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)